

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Endocrine disease</b>				
Hyperparathyroidism	Calcium sensing receptor (CaSR)	<p>Pyrazole-based type 2 calcimimetics that activate CaSR could help treat secondary hyperparathyroidism (SHPT). In rats, 3 mg/kg of one of the compounds led to greater reductions in circulating levels of parathyroid hormone (PTH) than 30 mg/kg of the first-generation calcimimetic compound R-568. Next steps could include evaluating the pyrazole-based calcimimetics in additional animal models of SHPT.</p> <p>R-568 is a first-generation calcimimetic from NPS Pharmaceuticals Inc. and Amgen Inc. that was discontinued due to its unfavorable pharmacokinetic and metabolic profile. Mimpara cinacalcet, a second-generation calcimimetic from NPS Pharmaceuticals, Amgen, Biovitrum AB and Kirin Brewery Co. Ltd., is marketed to treat hyperparathyroidism.</p> <p><b>SciBX 2(43); doi:10.1038/scibx.2009.1601</b>  <b>Published online Nov. 5, 2009</b></p>	Patent and licensing status unavailable	<p>Poon, S.F. <i>et al. J. Med. Chem.</i>; published online Oct. 16, 2009; doi:10.1021/jm9012278</p> <p><b>Contact:</b> David J. St. Jean Jr., Amgen Inc., Thousand Oaks, Calif.  e-mail: <a href="mailto:david.st.jean@amgen.com">david.st.jean@amgen.com</a></p> <p><b>Contact:</b> Steve F. Poon, same affiliation as above  e-mail: <a href="mailto:spoon@amgen.com">spoon@amgen.com</a></p>